PI3Kinase signaling in glioblastoma

Journal of Neuro-Oncology

Volumn 103, Issue 3, 2011, Pages 417-427

  Lino, M M ^a   Merlo, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Apoptosis; GBM; PI3K; Proliferation

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPOTHILONE B; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; HYDROXYUREA; IMATINIB; LYMPHOSIGN; MAMMALIAN TARGET OF RAPAMYCIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 528; MONOCLONAL ANTIBODY 806; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; NIMOTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; WORTMANNIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ASTROCYTOMA; BREAST CANCER; CANCER INHIBITION; CANCER RELAPSE; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; COLORECTAL CANCER; ENDOMETRIUM CANCER; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; MOLECULAR GENETICS; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHOSPHATASE AND TENSIN HOMOLOGUE GENE; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

BRAIN NEOPLASMS; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; MODELS, BIOLOGICAL; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 79959794242     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0442-z     Document Type: Review

References (156)

1. Newton HB (1994) Primary brain tumors: review of etiology, diagnosis and treatment. Am Fam Physician 49(4):787-797
2. Davis FG, McCarthy BJ (2001) Current epidemiological trends and surveillance issues in brain tumors. Expert Rev Anticancer Ther 1(3):395-401 (Pubitemid 34679431)
3. Newton HB (2004) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 4(1):105-128
4. Kleihues P, Sobin LH (2000) World Health Organization classification of tumors. Cancer 88(12):2887
5. Chung RY, Seizinger BR (1991) Tumor suppressor genes and cancer of the human nervous system. Cancer Invest 9(4):429-437
6. Maher EA, Furnari FB, Bachoo RM et al (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15(11):1311-1333 (Pubitemid 32524640)
7. von Deimling A, Louis DN, Wiestler OD (1995) Molecular pathways in the formation of gliomas. Glia 15(3):328-338
8. Knobbe CB, Merlo A, Reifenberger G (2002) Pten signaling in gliomas. Neuro-Oncology 4(3):196-211
9. Wong AJ, Ruppert JM, Bigner SH et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89(7):2965-2969
10. Hurtt MR, Moossy J, Donovan-Peluso M, Locker J (1992) Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis. J Neuropathol Exp Neurol 51(1):84-90
11. Merlo A, Herman JG, Mao L et al (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1(7):686-692
12. Smith JS, Tachibana I, Passe SM et al (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93(16):1246-1256 (Pubitemid 32816199)
13. Fueyo J, Gomez-Manzano C, Yung WK et al (1996) Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103-110 (Pubitemid 26041245)
14. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479-489 (Pubitemid 40781150)
15. Watanabe K, Sato K, Biernat W et al (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3(4):523-530 (Pubitemid 27211828)
16. Pomerantz J, Schreiber-Agus N, Liegeois NJ et al (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92(6):713-723 (Pubitemid 28155311)
17. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145(5):1175-1190 (Pubitemid 24345665)
18. Hiraga S, Ohnishi T, Izumoto S et al (1998) Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 58(10):2117-2125 (Pubitemid 28232897)
19. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
20. Boulay JL, Miserez AR, Zweifel C et al (2007) Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE 2(6):e576
21. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98-110
22. Wrensch M, Jenkins RB, Chang JS et al (2009) Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 41(8):905-908
23. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997-1003 (Pubitemid 40349502)
24. Hegi ME, Liu L, Herman JG et al (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189-4199
25. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343(19):1350-1354
26. (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068
27. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-Oncology 1(1):44-51
28. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353(19):2012-2024 (Pubitemid 41609094)
29. Kapoor GS, Christie A, O'Rourke DM (2007) EGFR inhibition in glioblastoma cells induces G2/M arrest and is independent of p53. Cancer Biol Ther 6(4):571-579 (Pubitemid 47328332)
30. Liliental J, Moon SY, Lesche R et al (2000) Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol 10(7):401-404 (Pubitemid 30213387)
31. Datta SR, Dudek H, Tao X et al (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231-241 (Pubitemid 27456390)
32. Holland EC, Hively WP, DePinho RA, Varmus HE (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12(23):3675-3685 (Pubitemid 29019648)
33. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S (2001) Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 21(16):5644-5657 (Pubitemid 32702467)
34. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103(2):211-225
35. Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63(20):6962-6970 (Pubitemid 37322983)
36. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60(5):1383-1387 (Pubitemid 30152011)
37. Heimberger AB, Suki D, Yang D, Shi W, Aldape K (2005) The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3:38
38. Fan QW, Cheng C, Knight ZA et al (2009) EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal 2(55):ra4
39. Vogt PK, Kang S (2006) Kinase inhibitors: vice becomes virtue. Cancer Cell 9(5):327-328 (Pubitemid 43668736)
40. Vogt PK, Bader AG, Kang S (2006) PI 3-kinases: hidden potentials revealed. Cell Cycle 5(9):946-949
41. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17:615-675 (Pubitemid 33096187)
42. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655-1657
43. Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104(13):5569-5574 (Pubitemid 47175721)
44. Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554 (Pubitemid 38541907)
45. Gaidarov I, Smith ME, Domin J, Keen JH (2001) The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol Cell 7(2):443-449 (Pubitemid 32206511)
46. Byfield MP, Murray JT, Backer JM (2005) hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280(38):33076-33082 (Pubitemid 41368357)
47. Nobukuni T, Joaquin M, Roccio M et al (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102(40):14238-14243 (Pubitemid 41429682)
48. Odorizzi G, Babst M, Emr SD (2000) Phosphoinositide signaling and the regulation of membrane trafficking in yeast. Trends Biochem Sci 25(5):229-235 (Pubitemid 30236220)
49. Burgering BM, Medema RH (2003) Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol 73(6):689-701 (Pubitemid 38040447)
50. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489-501 (Pubitemid 37328931)
51. Van Haastert PJ, Devreotes PN (2004) Chemotaxis: signalling the way forward. Nat Rev Mol Cell Biol 5(8):626-634 (Pubitemid 39025063)
52. Dugani CB, Klip A (2005) Glucose transporter 4: cycling, compartments and controversies. EMBO Rep 6(12):1137-1142 (Pubitemid 41741696)
53. Murga C, Zohar M, Teramoto H, Gutkind JS (2002) Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 21(2):207-216 (Pubitemid 34102129)
54. Nguyen KT, Zong CS, Uttamsingh S et al (2002) The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation. J Biol Chem 277(13):11107-11115 (Pubitemid 34952871)
55. Disanza A, Steffen A, Hertzog M, Frittoli E, Rottner K, Scita G (2005) Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement. Cell Mol Life Sci 62(9):955-970 (Pubitemid 40655613)
56. Yamazaki D, Kurisu S, Takenawa T (2005) Regulation of cancer cell motility through actin reorganization. Cancer Sci 96(7):379-386 (Pubitemid 41179738)
57. Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A (2005) PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 109(6):639-642 (Pubitemid 40974153)
58. Campbell IG, Russell SE, Choong DY et al (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21):7678-7681 (Pubitemid 39446895)
59. Broderick DK, Di C, Parrett TJ et al (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64(15):5048-5050 (Pubitemid 39006515)
60. Lee JW, Soung YH, Kim SY et al (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8):1477-1480 (Pubitemid 40343128)
61. Wymann MP, Marone R (2005) Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol 17(2):141-149 (Pubitemid 40380937)
62. Foukas LC, Claret M, Pearce W et al (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441(7091):366-370 (Pubitemid 44050203)
63. Gallia GL, Rand V, Siu IM et al (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4(10):709-714 (Pubitemid 44683311)
64. Li J, Yen C, Liaw D et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943-1947 (Pubitemid 27148818)
65. Maier D, Zhang Z, Taylor E et al (1998) Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas. Oncogene 16(25):3331-3335 (Pubitemid 28330433)
66. Knobbe CB, Reifenberger J, Blaschke B, Reifenberger G (2004) Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst 96(6):483-486 (Pubitemid 38443652)
67. Knobbe CB, Trampe-Kieslich A, Reifenberger G (2005) Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol Appl Neurobiol 31(5):486-490 (Pubitemid 41337782)
68. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25(1):55-57 (Pubitemid 30257036)
69. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19(4):348-355 (Pubitemid 28357906)
70. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606-619 (Pubitemid 44100518)
71. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H (2003) PTEN methylation and expression in glioblastomas. Acta Neuropathol 106(5):479-485 (Pubitemid 37265852)
72. Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T (2005) Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res 65(12):5172-5180 (Pubitemid 40827326)
73. Wei Q, Clarke L, Scheidenhelm DK et al (2006) High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66(15):7429-7437 (Pubitemid 44289195)
74. Adachi J, Ohbayashi K, Suzuki T, Sasaki T (1999) Cell cycle arrest and astrocytic differentiation resulting from PTEN expression in glioma cells. J Neurosurg 91(5):822-830 (Pubitemid 30053155)
75. Groszer M, Erickson R, Scripture-Adams DD et al (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294(5549):2186-2189 (Pubitemid 33150679)
76. Groszer M, Erickson R, Scripture-Adams DD et al (2006) PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 103(1):111-116 (Pubitemid 43076113)
77. Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M (1999) PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18(27):3936-3943 (Pubitemid 29361331)
78. Ermoian RP, Furniss CS, Lamborn KR et al (2002) Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8(5):1100-1106 (Pubitemid 34517646)
79. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN (2001) PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 159(1):359-367 (Pubitemid 33704221)
80. Ueki K, Yballe CM, Brachmann SM et al (2002) Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 99(1):419-424 (Pubitemid 34060376)
81. Terauchi Y, Tsuji Y, Satoh S et al (1999) Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 21(2):230-235 (Pubitemid 29070374)
82. Mauvais-Jarvis F, Ueki K, Fruman DA et al (2002) Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109(1):141-149 (Pubitemid 34052550)
83. Bi L, Okabe I, Bernard DJ, Nussbaum RL (2002) Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome 13(3):169-172 (Pubitemid 34185317)
84. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL (1999) Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J Biol Chem 274(16):10963-10968
85. Jia S, Liu Z, Zhang S et al (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454(7205):776-779
86. Lefranc F, Brotchi J, Kiss R (2005) Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 23(10):2411-2422 (Pubitemid 46218735)
87. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996 (Pubitemid 40349501)
88. Kneifel S, Cordier D, Good S et al (2006) Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1- glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 12(12):3843-3850
89. Merlo A, Hausmann O, Wasner M et al (1999) Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 5(5):1025-1033 (Pubitemid 29233216)
90. Raizer JJ, Malkin MG, Kleber M, Abrey LE (2004) Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. Neuro-Oncology 6(3):247-252 (Pubitemid 39139535)
91. Reardon DA, Egorin MJ, Quinn JA et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23(36):9359-9368
92. Pfeffer MR, Levitt ML, Aderka D (2004) Gefitinib in recurrent glioblastoma. J Clin Oncol 22(13):2755-2756; author reply 2756
93. Groves MD, Puduvalli VK, Hess KR et al (2002) Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20(5):1383-1388 (Pubitemid 34177446)
94. Baka S, Clamp AR, Jayson GC (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10(6):867-876 (Pubitemid 44816749)
95. Puduvalli VK (2004) Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res 117:307-336
96. Lamszus K, Heese O, Westphal M (2004) Angiogenesis-related growth factors in brain tumors. Cancer Treat Res 117:169-190
97. Morabito A, Fanelli M, Carillio G, Gattuso D, Sarmiento R, Gasparini G (2004) Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep 11(1):93-95
98. Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2(12):689-700 (Pubitemid 44764211)
99. Luwor RB, Johns TG, Murone C et al (2001) Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 61(14):5355-5361 (Pubitemid 32694909)
100. Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6):1207-1218
101. Eller JL, Longo SL, Hicklin DJ, Canute GW (2002) Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 51(4):1005-1013; discussion 1013-1004
102. Baselga J (2001) The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 37(Suppl 4):S16-S22
103. Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22(1):133-142 (Pubitemid 41095125)
104. Daneshmand M, Parolin DA, Hirte HW et al (2003) A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res 9(7):2457-2464 (Pubitemid 36842084)
105. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527-1537 (Pubitemid 41540110)
106. Failly M, Korur S, Egler V et al (2007) Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Mol Cancer Ther 6(2):773-781 (Pubitemid 46332478)
107. Fan QW, Cheng CK, Nicolaides TP et al (2007) A dual phosphoinositide-3- kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67(17):7960-7965 (Pubitemid 47395125)
108. Mukherjee B, McEllin B, Camacho CV et al (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69(10):4252-4259
109. Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J (2008) Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol 90(1):9-17
110. Arcaro A, Wymann MP (1993) Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J 296(Pt 2):297-301 (Pubitemid 23350826)
111. Walker EH, Pacold ME, Perisic O et al (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6(4):909-919
112. Toledo LM, Lydon NB, Elbaum D (1999) The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 6(9):775-805 (Pubitemid 29422195)
113. Meier F, Busch S, Lasithiotakis K et al (2007) Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 156(6):1204-1213 (Pubitemid 47029801)
114. Schultz RM, Merriman RL, Andis SL et al (1995) In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 15(4):1135-1139
115. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ (2002) Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1(12):989-997
116. Klingler-Hoffmann M, Bukczynska P, Tiganis T (2003) Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int J Cancer 105(3):331-339 (Pubitemid 36570045)
117. Kubota N, Okada S, Inada T, Ohnishi K, Ohnishi T (2000) Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation. Cancer Lett 161(2):141-147
118. Shingu T, Yamada K, Hara N et al (2003) Growth inhibition of human malignant glioma cells induced by the PI3-K-specific inhibitor. J Neurosurg 98(1):154-161 (Pubitemid 36050459)
119. Bar J, Lukaschuk N, Zalcenstein A, Wilder S, Seger R, Oren M (2005) The PI3K inhibitor LY294002 prevents p53 induction by DNA damage and attenuates chemotherapy-induced apoptosis. Cell Death Differ 12:1578-1587 (Pubitemid 41679163)
120. Fan QW, Knight ZA, Goldenberg DD et al (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5):341-349 (Pubitemid 43668732)
121. Fan QW, Weiss WA (2006) Isoform specific inhibitors of PI3 kinase in glioma. Cell Cycle 5(20):2301-2305
122. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S (2008) Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68(15):6271-6280
123. Costa BM, Smith JS, Chen Y et al (2010) Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res 70(2):453-462
124. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278(5338):687-689 (Pubitemid 27464966)
125. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90(9):3322-3331 (Pubitemid 27473400)
126. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D (1998) Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8(21):1195-1198 (Pubitemid 28494720)
127. Sonoda Y, Ozawa T, Hirose Y et al (2001) Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61(13):4956-4960 (Pubitemid 32681517)
128. Koul D, Shen R, Bergh S et al (2006) Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 5(3):637-644
129. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18(16):1926-1945 (Pubitemid 39071573)
130. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103(2):253-262
131. Busca R, Bertolotto C, Ortonne JP, Ballotti R (1996) Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem 271(50):31824-31830 (Pubitemid 26422202)
132. Grewe M, Gansauge F, Schmid RM, Adler G, Seufferlein T (1999) Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res 59(15):3581-3587 (Pubitemid 29381856)
133. Huang S, Houghton PJ (2001) Mechanisms of resistance to rapamycins. Drug Resist Updat 4(6):378-391 (Pubitemid 34746872)
134. Houghton PJ, Huang S (2004) mTOR as a target for cancer therapy. Curr Top Microbiol Immunol 279:339-359 (Pubitemid 37047272)
135. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S (1998) Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273(23):14424-14429 (Pubitemid 28319162)
136. Castedo M, Roumier T, Blanco J et al (2002) Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 21(15):4070-4080 (Pubitemid 34857439)
137. Decaudin D, Geley S, Hirsch T et al (1997) Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57(1):62-67 (Pubitemid 27020331)
138. Balcarcel RR, Stephanopoulos G (2001) Rapamycin reduces hybridoma cell death and enhances monoclonal antibody production. Biotechnol Bioeng 76(1):1-10 (Pubitemid 33081199)
139. Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128-135 (Pubitemid 34155123)
140. Liu TJ, Koul D, LaFortune T et al (2009) NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8(8):2204-2210
141. Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M, Wouters BG (2007) Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis. Radiother Oncol 82(1):96-104 (Pubitemid 46097131)
142. Panner A, Parsa AT, Pieper RO (2006) Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Expert Rev Anticancer Ther 6(9):1313-1322 (Pubitemid 44575582)
143. Ferretti G (2007) Temsirolimus for advanced renal-cell carcinoma. N Engl J Med 357(10):1050; author reply 1050-1051
144. Zhou C, Gehrig PA, Whang YE, Boggess JF (2003) Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2(8):789-795
145. Witzig TE, Geyer SM, Ghobrial I et al (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23(23):5347-5356 (Pubitemid 46206988)
146. Galanis E, Buckner JC, Maurer MJ et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23(23):5294-5304 (Pubitemid 46206983)
147. Chang SM, Wen P, Cloughesy T et al (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investig New Drugs 23(4):357-361 (Pubitemid 40980358)
148. Beier D, Hau P, Proescholdt M et al (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67(9):4010-4015 (Pubitemid 46815044)
149. Li B, Chang CM, Yuan M, McKenna WG, Shu HK (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63(21):7443-7450 (Pubitemid 37413487)
150. Rao RD, Mladek AC, Lamont JD et al (2005) Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7(10):921-929
151. Efferth T, Ramirez T, Gebhart E, Halatsch ME (2004) Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 67(9):1689-1700 (Pubitemid 38479847)
152. Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9(3):231-241 (Pubitemid 351301823)
153. Lyustikman Y, Momota H, Pao W, Holland EC (2008) Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia 10(5):501-510 (Pubitemid 351657392)
154. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA (2006) Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 103(48):18238-18242 (Pubitemid 44871642)
155. Rosato RR, Grant S (2003) Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2(1):30-37
156. Egler V, Korur S, Failly M et al (2008) Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death. Clin Cancer Res 14(10):3132-3140